Skip to main content

Table 2 Results of the univariate and multivariate analyses of progression-free survival in 46 patients with stage III-IV gastric cancer treated with neoadjuvant chemotherapy

From: Blood neutrophil-lymphocyte ratio predicts survival for stages III-IV gastric cancer treated with neoadjuvant chemotherapy

Factors Number Univariate analysisa, P value Multivariate analysisb,
HR (95% CI) P value
Radicality     
 R0 37   0.163 (0.063 to 0.421) <0.001
 R1     
 R2 9 <0.001 1  
Differentiation     
 Differentiatedc 15    
 Poorly differentiatedd 31 0.039   
Pre-chemotherapy blood parameters     
 Neutrophils, cells/mm3     
  ≤4000 24    
  >4000 22 0.065   
 NLR     
  ≤2.5 22   1  
  >2.5 24 0.012 2.329 (1.069 to 5.073) 0.033
Pre-operative blood parameters e     
 Neutrophils, cells/mm3     
  ≤4000 34    
  >4000 12 0.049   
 NLR     
  ≤2.5 26   1  
  >2.5 20 0.019 2.347 (1.128 to 4.881) 0.022
  1. HR, hazard ratio; NLR, Neutrophil to lymphocyte ratio.
  2. aPerformed using the Kaplan-Meier analysis model and log-rank test; values of P<0.10 in the univariate analysis were entered into a multivariate analysis.
  3. bPerformed using Cox proportional hazards models with the backward likelihood method.
  4. cDifferentiated include: well and moderately differentiated adenocarcinoma.
  5. dPoorly differentiated include: poorly differentiated adenocarcinoma, ring cell carcinoma.